Clinical Oncology
Volume 18, Issue 7 , Pages 525-528 , September 2006

Radiosensitivity, Radiogenomics and RAPPER

  • N.G. Burnet

      Affiliations

    • Oncology Centre, Addenbrooke's Hospital, Cambridge, UK
    • Corresponding Author InformationAuthor for correspondence: Dr Neil Burnet, Cambridge University Department of Oncology, Oncology Centre (Box 193), Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. Tel: +44-1223-336800; Fax: +44-1223-763120.
    • ,
  • R.M. Elliott

      Affiliations

    • Academic Department of Radiation Oncology, Christie Hospital, Manchester, UK
    • ,
  • A. Dunning

      Affiliations

    • CRC Human Cancer Genetics Group, Strangeways Research Laboratory, Cambridge, UK
    • ,
  • C.M.L. West

      Affiliations

    • Academic Department of Radiation Oncology, Christie Hospital, Manchester, UK

Received 11 April 2006 ,Accepted 11 May 2006.

References 

  1. Benson RJ, Burnet NG. Altered radiotherapy fractionation: an opportunity not to be missed. Clin Oncol (R Coll Radiol). 1998;10:150–154
  2. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997;44:111–121
  3. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet. 1997;350:161–165
  4. Brenner DJ. Hypofractionation for prostate cancer radiotherapy—what are the issues?. Int J Radiat Oncol Biol Phys. 2003;57:912–914
  5. Logue JP, Cowan RA, Hendry JH. Hypofractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:1522–1523
  6. Holthusen H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen and deren Nutzanwendung zur Verhütung von Schäden. Strahlentherapie. 1936;57:254–269
  7. Turesson I. Individual variation and dose dependency in the progression rate of skin telangiectasia. Int J Radiat Oncol Biol Phys. 1990;19:1569–1574
  8. Turesson I. Characteristics of dose–response relationships for late radiation effects: an analysis of skin telangiectasia and of head and neck morbidity. Radiother Oncol. 1991;20:149–158
  9. Turesson I, Notter G. Skin reactions after different fractionation schedules giving the same cumulative radiation effect. Acta Radiol Ther Phys Biol. 1975;14:475–484
  10. Turesson I, Nyman J, Holmberg E, Oden A. Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys. 1996;36:1065–1075
  11. Turesson I, Thames HD. Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 years' follow-up. Radiother Oncol. 1989;15:169–188
  12. Bentzen SM, Overgaard M. Relationship between early and late normal-tissue injury after postmastectomy radiotherapy. Radiother Oncol. 1991;20:159–165
  13. Russell NS, Knaken H, Bruinvis IA, Hart AA, Begg AC, Lebesque JV. Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy. Radiother Oncol. 1994;30:213–221
  14. Burnet NG, Johansen J, Turesson I, Nyman J, Peacock JH. Describing patients' normal tissue reactions: concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. Steering Committee of the BioMed2 European Union Concerted Action Programme on the Development of Predictive Tests of Normal Tissue Response to Radiation Therapy. Int J Cancer. 1998;79:606–613
  15. Burnet NG, Wurm R, Nyman J, Peacock JH. Normal tissue radiosensitivity—how important is it?. Clin Oncol (R Coll Radiol). 1996;8:25–34
  16. MacKay RI, Niemierko A, Goitein M, Hendry JH. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother Oncol. 1998;46:215–216
  17. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer?. Am J Hum Genet. 1999;65:784–794
  18. Brock WA, Tucker SL, Geara FB, et al. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. Int J Radiat Oncol Biol Phys. 1995;32:1371–1379
  19. Burnet NG, Nyman J, Turesson I, Wurm R, Yarnold JR, Peacock JH. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity. Lancet. 1992;339:1570–1571
  20. Johansen J, Bentzen SM, Overgaard J, Overgaard M. Relationship between the in vitro radiosensitivity of skin fibroblasts and the expression of subcutaneous fibrosis, telangiectasia, and skin erythema after radiotherapy. Radiother Oncol. 1996;40:101–109
  21. Peacock J, Ashton A, Bliss J, et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol. 2000;55:173–178
  22. Dikomey E, Borgmann K, Peacock J, Jung H. Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys. 2003;56:1194–1200
  23. West CM, Davidson SE, Elyan SA, et al. Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2001;51:10–15
  24. Dickson J, Magee B, Stewart A, West CM. Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients. Radiother Oncol. 2002;62:321–326
  25. Kiltie AE, Orton CJ, Ryan AJ, et al. A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. Int J Radiat Oncol Biol Phys. 1997;39:1137–1144
  26. Hoeller U, Borgmann K, Bonacker M, et al. Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol. 2003;69:137–144
  27. Barber JB, West CM, Kiltie AE, Roberts SA, Scott D. Detection of individual differences in radiation-induced apoptosis of peripheral blood lymphocytes in normal individuals, ataxia telangiectasia homozygotes and heterozygotes, and breast cancer patients after radiotherapy. Radiat Res. 2000;153:570–578
  28. Carlomagno F, Burnet NG, Turesson I, et al. Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities. Int J Cancer. 2000;85:845–849
  29. Bremer M, Klopper K, Yamini P, Bendix-Waltes R, Dork T, Karstens JH. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol. 2003;69:155–160
  30. Cesaretti JA, Stock RG, Lehrer S, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:196–202
  31. Meyer A, John E, Dork T, Sohn C, Karstens JH, Bremer M. Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy. Radiother Oncol. 2004;72:319–323
  32. Anscher MS, Kong FM, Jirtle RL. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer. 1998;19:109–120
  33. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?. Acta Oncol. 2005;44:801–815
  34. Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol. 2005;75:18–21
  35. Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol. 2003;69:127–135
  36. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 2003;63:8717–8725
  37. Quarmby S, Fakhoury H, Levine E, et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol. 2003;79:137–143
  38. Baumann M, Holscher T, Begg AC. Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiother Oncol. 2003;69:121–125
  39. Abraham J, Earl HM, Poole CJ, et al. PG-SNPs: a pharmaco-genetic study of chemotherapy in early breast cancer trials. NCRI Cancer Conference; Poster 52:29.

PII: S0936-6555(06)00178-6

doi: 10.1016/j.clon.2006.05.007

Clinical Oncology
Volume 18, Issue 7 , Pages 525-528 , September 2006

Article Tools